Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596710 | 1.00 | TP53 (0.52) | TP53POLBLMNASLC6A9GRM2 | |
| SCHEMBL13037006 | 0.80 | TP53 (0.55) | TP53POLBLMNASLC6A9GRM2 | |
| SCHEMBL3582654 | 0.78 | CD274 (0.42) | TP53POLBLMNAMMP3MMP9 | |
| SCHEMBL3592403 | 0.74 | CCR2 (0.40) | — | |
| SCHEMBL30537252 | 0.74 | TP53 (0.55) | TP53POLBLMNAGRM2 | |
| SCHEMBL12128449 | 0.74 | TP53 (0.50) | TP53POLBLMNASLC6A9 | |
| SCHEMBL3592407 | 0.74 | CCR2 (0.40) | — | |
| SCHEMBL3588653 | 0.73 | ALDH1A1 (0.40) | LMNA | |
| SCHEMBL3588651 | 0.73 | ALDH1A1 (0.40) | LMNA | |
| SCHEMBL27692840 | 0.72 | CCR2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | claimed |
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | TP53 1114/4885POLB 4267/4885LMNA 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.